Teva Pharmaceuticals - Digital Audit

Enterprise Technology Stack & Vendor Relationships

No public evidence identified of a direct licensing, subscription, or integration relationship between Teva and Check Point, Wiz, SentinelOne, CyberArk, NICE, Verint, Claroty, or Palo Alto Networks; Teva’s Item 1C cybersecurity disclosure in its 10-K (filed 5 Feb 2025) names no specific vendors, stating only that it engages unspecified “third-party consultants and other service providers” and is certified to ISO 27001 ¹. External attack-surface scanning by UpGuard was likewise unable to identify Teva’s internal vendor stack, consistent with the absence of public vendor-specific disclosure ². Teva’s Global CISO, Ilan Abadi, has an Israeli security-sector career background - CISO at the Israel National Police, CISO at Ness Technologies, and Head of Information Security at YES Television - prior to joining Teva around 2012–2017, though no direct Unit 8200 affiliation is documented for him specifically ³⁴. Teva Respiratory’s Digihaler digital-inhaler platform uses Amazon Web Services as its cloud infrastructure provider, built with implementation partner Onica, as announced 21 October 2020 ⁵. Teva has run SAP SuccessFactors Employee Central as its global cloud HR system since 2017, a $10m+ investment live in more than 60 countries, supplemented by Qlik Sense analytics ⁶. Teva engages Accenture, using India-based data processing, for pharmacovigilance data entry, administration and cleansing, per Teva’s own Privacy Notice ⁷. No public evidence identified of Teva being mandated or steered toward Israeli-origin technology via a systems-integrator engagement (Accenture, TCS, Infosys, Wipro). Teva’s FY2025 proxy statement and board-of-directors page list current governance personnel, but individual director biographies beyond former CFO Eyal Desheh were not each reviewed in this pass for defence- or intelligence-sector ties ⁸⁹.

Surveillance, Biometrics & Retail Technology

No public evidence identified of Teva’s use of Trigo, BriefCam, AnyVision/Oosto, Trax, or comparable Israeli-origin facial-recognition, biometric, or gait-analysis products for retail, loss-prevention, or workforce purposes; Teva’s profile as a pharmaceutical manufacturer and distributor rather than a retailer further reduces the applicability of this sub-category. No public evidence identified of independent verification, beyond company AI-feature material, of Teva’s reported use of AI-based facial-landmark analysis of mobile video to identify symptoms of tardive dyskinesia. No public evidence identified of Israeli-origin predictive-policing, sentiment-analysis, social-media-monitoring, or workforce-surveillance tools in use by Teva. No public evidence identified of indirect or bundled delivery of such technologies to Teva via managed security service providers.

Cloud Infrastructure, Data Residency & Sovereign Cloud Participation

Teva Pharmaceutical Industries Ltd, the Israeli parent entity headquartered in the Tel Aviv/Petach Tikva area, hosts and stores certain personal-data databases on servers it owns or maintains; Teva’s UK privacy policy states that data-subject information may be processed by “other companies in the Teva group of companies worldwide located in the European Economic Area and beyond such as India, Israel, and the USA,” relying on UK ICO/EU Commission adequacy decisions for transfers to Israel ¹⁰. Teva’s Argentina entity publishes a similarly structured privacy policy describing group-wide, cross-border data-processing arrangements ¹¹. Teva’s pharmacovigilance database is located in the United States but is “administered and supported by Teva’s pharmacovigilance teams in Israel and India,” per Teva’s corporate privacy notice ⁷. No public evidence identified of Teva’s direct participation in Project Nimbus, the Google/Amazon-Israeli-government cloud programme. No public evidence identified that Teva markets or contracts data-sovereignty or resilience services to Israeli state or military institutions; on current evidence Teva functions as a data controller/processor customer within Israeli jurisdiction rather than as a sovereign-cloud vendor.

Defence, Intelligence & Security Sector Technology Relationships

No public evidence identified of direct IT or technology contracts between Teva and Israel’s Ministry of Defence, the IDF, or Israeli intelligence agencies. Teva’s Israeli logistics/distribution subsidiary continued operating during the Gaza war; the CEO of that logistics company, Hadar Mama, served as an active IDF reservist in Gaza while continuing to make company decisions remotely, per the StopTeva campaign report ¹². Teva partnered with the NGO “Thank Israeli Soldiers” (TIS), which develops psychological-support programmes “in coordination with the IDF,” funding professional supervision for TIS facilitators under Teva’s “Support the Soul” programme launched after 7 October 2023 ¹³¹². Teva participated in the IDF’s “Adopt a Battalion” reservist financial and mental-health support programme in past years and was recognised by the IDF in 2009 for an “exemplary” relationship with reservist employees, with some form of this relationship reported as continuing ¹³¹². At least 10% of Teva’s Israeli workforce - several hundred employees - were called up for IDF reserve duty following 7 October 2023 ¹³. No public evidence identified of Teva development, sale, licensing, or maintenance of offensive cyber capabilities or digital-weapons systems.

AI, Algorithmic & Autonomous Systems

Teva is a founding pharmaceutical partner - alongside AstraZeneca, Merck KGaA, and Pfizer - of AION Labs, an Israeli AI-drug-discovery venture studio launched in 2021 following a December 2020 Israel Innovation Authority tender; other partners include venture funds Israel Biotech Fund and Amiti Ventures, technology partner Amazon Web Services, and research institute BioMed X ¹⁴¹⁵. Teva is a named industry partner in the “Israel BioToken Factory Initiative” (IBFI), a roughly NIS 70 million national AI-infrastructure consortium announced 12 July 2026 by the Israel Innovation Authority alongside NVIDIA, Sheba Medical Center, CytoReason, TerraCyte Analytics, MeMed, the Weizmann Institute, the Technion, and Ben-Gurion University, building shared “Bio Token”/“Factory Model” AI infrastructure for drug discovery and clinical decision support such as oncology treatment prediction, immune evaluation, and drug-sensitivity analysis ¹⁶¹⁷. These AI collaborations are general-purpose biomedical and drug-discovery platforms with explicit civilian pharmaceutical application, and no evidence connects them to targeting, kill-chain, or military decision-support use ^14151617. No public evidence identified of Teva AI models being trained on intercepted communications, surveillance-derived data, or occupied-territory population datasets. No public evidence identified of Teva providing autonomous target-generation, automated threat-detection, or autonomous-tracking systems to Israeli military or security forces.

Technology Ecosystem & R&D Footprint

Teva operates multiple Israeli R&D and manufacturing facilities, including a development/manufacturing site in Netanya, a manufacturing/R&D facility in Kfar Saba, and a raw-materials/API plant at Neot Hovav (Ramat Hovav) near Beersheba; the Neot Hovav site was struck during the Iran-Israel missile exchange, and Teva stated operations remained stable ¹⁸. Israel accounts for approximately 8% of Teva’s global production, per Forbes reporting from October 2023 ¹⁹. In 2025 Teva launched “Rise,” a global open-innovation platform for AI, Industry 4.0, smart manufacturing, digital health, and biotech, seeking Israeli and international startup partners across seven R&D, manufacturing, supply-chain, and commercial challenges, and was reported to be evaluating a dedicated innovation centre in Israel to anchor Rise’s first challenge cycle ²⁰²¹. Teva has approximately 30 active academic-research collaborations with Israeli institutions including Hebrew University, Tel Aviv University, the Technion, and the Weizmann Institute; a specific Weizmann Institute collaboration with the Rony Dahan lab applies computational biology and single-cell analysis to cancer antibody discovery ²². Former Teva CFO Eyal Desheh, who is no longer on Teva’s board, has since taken chairman or director roles at Tevel Aerobotics Technologies, at MigVax (appointed alongside recognition of his prior Check Point executive background), and at Mobileye (director since October 2022), illustrating personnel linkages between Teva’s former leadership and Israel’s wider technology sector ²³²⁴²⁵. No public evidence identified of Teva acquisitions of Israeli cybersecurity, surveillance, or AI-defence technology companies; the historical acquisitions identified, such as CoGenesys in 2008, are conventional biopharma transactions rather than dual-use technology deals.

Civil Society Scrutiny & Regulatory History

Who Profits lists Teva under “Economic Exploitation”/“Palestinian Captive Market,” documenting Teva’s benefit from Paris Protocol trade asymmetries that give it duty- and checkpoint-free access to Palestinian markets while Palestinian pharmaceutical companies face licensing and export burdens; the entry’s detailed data is dated to 2012, indicating the listing has not been substantively refreshed in the current database snapshot ²⁶. AFSC Investigate documents the same “captive market” dynamic, noting Teva can sell products not labelled in Arabic and faces reduced competition from Palestinian generics due to Israeli Ministry of Health registration restrictions enforced in the occupied Palestinian territories ²⁷. Secondary reporting on Teva’s inclusion in the UN OHCHR settlement-business database directly conflicts: Middle East Monitor’s February 2020 report on the 112-company UN list named Teva as included ²⁸, while a contemporaneous annotated account states the officially published 12 February 2020 UN database does not include Teva and that later media claims of its inclusion are not reflected in official UN documents ²⁹; OHCHR announced a further update to this database in September 2025 ³⁰. UN Special Rapporteur Francesca Albanese’s report “From economy of occupation to economy of genocide” (A/HRC/59/23, 2 July 2025) addresses corporate complicity broadly across arms, technology, banking, and construction sectors ³¹; No public evidence identified of Teva being specifically named in that report’s technology- or surveillance-focused sections, consistent with Teva’s profile as a market-access beneficiary rather than a technology-surveillance provider. Al-Haq and SOMO commissioned a June 2024 legal opinion, “Obligations of Third States and Corporations to Prevent and Punish Genocide,” used by the Palestine solidarity movement as part of a corporate-complicity case against Teva, which campaigners describe as having “actively supported” and “benefited from” the occupation ³². The Netherlands-based StopTeva campaign published “Teva and the IDF” on 15 June 2025, documenting reservist call-ups, the Hadar Mama case, and the “Thank Israeli Soldiers” partnership ¹². Declassified UK’s investigation states Teva supplies approximately 14–15% of prescribed medicine packs to the UK NHS (reportedly up to £500m/year as of 2017) and documents the TIS/IDF partnership, with critics calling on the UK government to seek alternative suppliers ¹³. More than 30 activists protested outside a UK Teva facility on 4 March 2024 calling for a boycott under the banner “Boycott Teva Pharma No to Apartheid Drugs!” ³³. A public petition campaign seeks Teva’s removal from the UN Global Compact list of participants, citing a pattern of corruption and anti-competitive conduct - including price-fixing and FCPA-related allegations - rather than technology-specific grounds ³⁴. Norway’s Sykehusinnkjop (Hospital Procurement Trust) commissioned a KPMG “Targeted Research” report on Teva dated 19 December 2024, indicating institutional-buyer human-rights due diligence on Teva was underway as a matter of public procurement record ³⁵. No public evidence identified of any regulatory inquiry, export-control action, or sanctions investigation specifically targeting Teva’s technology sales or services to Israeli state entities, as distinct from Teva’s separately documented pharmaceutical pricing and marketing regulatory history.

End Notes